Gujarat Themis Biosyn Q2 FY27 Results Preview: Date and Trend
- September 18, 2026
- Posted by: Harsh Piplani
- Category: Results
Gujarat Themis Biosyn CMP Rs 420.15. Q1 FY27 (Jun26) revenue Rs 44 Cr, net profit Rs 11 Cr, OPM 47.73%. Results date not yet announced.
The Gujarat Themis Biosyn Q2 results for this pharma intermediates and API maker are likely to be announced in late October or November 2026, based on its historical filing pattern, though the company has not yet confirmed an exact board meeting date. Investors tracking the Gujarat Themis Biosyn Q2 results should rely on the official exchange filing once it is out. Track the latest Gujarat Themis Biosyn share price on Univest for updates.
Open a free demat account with Univest to track Gujarat Themis Biosyn ahead of results
What to Expect From the Gujarat Themis Biosyn Q2 Results
No analyst estimate is available for the September 2026 quarter, so expectations for the Gujarat Themis Biosyn Q2 results are best built around the company’s consistently high and stable operating margin, which has stayed between 39 percent and 49 percent across the last five quarters. That level of margin stability is unusual and is the single most notable qualitative feature going into the Gujarat Themis Biosyn Q2 results.
Revenue has grown steadily from Rs 36 Cr in June 2025 to Rs 44 Cr in the last two quarters, while net profit has held in a Rs 9 Cr to Rs 14 Cr range. This steady, profitable pattern is the backdrop for the Gujarat Themis Biosyn Q2 results, rather than a specific number that can be forecast.
Also read – Premier Energies Q2 Results FY27 Preview
Previous Quarter: Q1 FY27 (June 2026) Actuals
In the quarter ended June 2026, Gujarat Themis Biosyn Ltd. reported revenue of Rs 44 Cr, matching the March 2026 quarter, operating profit of Rs 21 Cr and an operating margin of 47.73 percent. Net profit came in at Rs 11 Cr, in line with the recent range, providing the most current base for the Gujarat Themis Biosyn Q2 results.
Base Quarter: Q2 FY26 (September 2025)
The year-ago quarter the Gujarat Themis Biosyn Q2 results will be compared against is September 2025, when Gujarat Themis Biosyn posted revenue of Rs 42 Cr, operating profit of Rs 21 Cr, an operating margin of 49 percent, its best of the five quarters, and net profit of Rs 14 Cr, also its highest of the period.
Five-Quarter Trend
| Quarter | Revenue (Rs Cr) | OPM | Net Profit (Rs Cr) |
|---|---|---|---|
| Jun 2025 | 36 | 39.00% | 9 |
| Sep 2025 | 42 | 49.00% | 14 |
| Dec 2025 | 43 | 48.84% | 12 |
| Mar 2026 | 44 | 43.18% | 11 |
| Jun 2026 | 44 | 47.73% | 11 |
Across five quarters, revenue has grown modestly while margin has stayed consistently high, making this one of the steadier profiles among small pharma intermediates names heading into the Gujarat Themis Biosyn Q2 results.
Track Gujarat Themis Biosyn and open your free demat account on Univest
Key Factors to Watch
Also read – Indiamart Intermesh Q2 Results FY27 Preview
Demand for the company’s key pharma intermediate products, raw material cost trends, and capacity utilisation will shape the Gujarat Themis Biosyn Q2 results. The company’s promoter shareholding structure, including a disclosed share pledge, is also a governance data point long-term holders track alongside quarterly numbers.
Valuation Snapshot
At Rs 420.15, Gujarat Themis Biosyn Ltd. trades at a trailing PE of about 112.04, a price-to-book ratio of 15.91 and a return on equity of 17.4 percent, reflecting the market’s premium for its high and stable margin profile. The 52-week range is Rs 225 to Rs 479, with a dividend yield of 0.16 percent.
Get started on Univest and open your demat account before the results season
What to Watch Around the Gujarat Themis Biosyn Q2 Results
Whether operating margin can hold near the 47 to 49 percent band seen in the last three quarters is the key thing to watch in the Gujarat Themis Biosyn Q2 results. Confirmation of the board meeting date will be the first concrete signal ahead of the Gujarat Themis Biosyn Q2 results.
Conclusion
Gujarat Themis Biosyn Ltd. heads into its September 2026 quarter with one of the steadier, higher-margin profiles in this results season. The Gujarat Themis Biosyn Q2 results will show whether that consistency continues, and investors should base decisions on the confirmed filing rather than any speculation around the Gujarat Themis Biosyn Q2 results.
Disclaimer: Univest Securities Private Limited is a SEBI-registered Research Analyst (Registration No. INH000013776). The content above is for educational and informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. All figures are drawn from historical, publicly disclosed quarterly financials and current market data; no specific Q2 FY27 results, estimates, or forecasts are implied. Please consult a SEBI-registered investment adviser and verify all data independently before making any investment decision.
When will Gujarat Themis Biosyn announce its Q2 FY27 results?
Gujarat Themis Biosyn Ltd. has not officially confirmed its Q2 FY27 results date. Based on its historical pattern, the announcement is likely in late October or November 2026.
What was Gujarat Themis Biosyn’s operating margin in the previous quarter?
In Q1 FY27 (June 2026), Gujarat Themis Biosyn Ltd. reported an operating margin of 47.73 percent on revenue of Rs 44 Cr, with a net profit of Rs 11 Cr.
Has Gujarat Themis Biosyn’s margin been consistent?
Yes, Gujarat Themis Biosyn has maintained an operating margin between 39 percent and 49 percent across the last five quarters, one of the more stable profiles among small pharma intermediates companies.
What is Gujarat Themis Biosyn’s current valuation?
Gujarat Themis Biosyn shares trade around Rs 420.15, with a trailing PE of about 112.04, a price-to-book ratio of 15.91 and a return on equity of 17.4 percent.
